Login / Signup

Intra-arterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients.

Evert-Jan P A VonkenRutger C G BruijnenTom J SnijdersTatjana SeuteMarnix G E H LamBart de KeizerArthur Johannes Anthonius Theodorus Braat
Published in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
INTRODUCTION: Intravenous 177Lu-(HA-)DOTATATE has shown promising results for the treatment of surgery- and radiotherapy-refractory meningiomas. We aimed to investigate the added value of intra-arterial administration. METHODS: Patients underwent at least one intravenous 177Lu-HA-DOTATATE treatment first and subsequent intra-arterial cycles. In(tra)-patient comparison was based on post-treatment 177Lu-HA-DOTATATE imaging 24 hours post-injection. Technical success rates and adverse events were recorded. RESULTS: Four patients provided informed consent. Technical success rate was 100% and no angiography related or unexpected adverse events occurred. Intra-patient comparison showed an increased target lesion accumulation on both planar imaging (mean +220%) and SPECT/CT (mean +398%) after intra-arterial administration compared to intravenous. No unexpected adverse events during follow-up occurred. CONCLUSION: Intra-arterial PRRT significantly increases tracer accumulation, and is a safe and promising improvement for salvage meningioma patients. Future prospective studies on intra-arterial PRRT are needed to determine gain on efficacy and survival.
Keyphrases